Literature DB >> 9358242

Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture.

U M Agren1, R H Tammi, M I Tammi.   

Abstract

Hyaluronan (HA) is produced by keratinocytes in human skin organ culture, and degraded locally in epidermis by an unknown metabolic route. The present work tested whether reactive oxygen species (ROS), spontaneously produced in the tissue, could contribute to HA catabolism in epidermis. Epidermal HA was endogenously labeled with 3H-glucosamine for 24 h, then chased for 24 h in the presence of superoxide dismutase (SOD) and catalase to reduce the concentration of ROS. In control cultures, 35% of labeled HA was degraded during the 24 h chase while the corresponding figures in the presence of SOD and catalase were 19% and 23%, respectively (p < 0.05). Methionine, a quencher of hypochlorous acid, did not significantly inhibit the degradation. In additional experiments, the iron and copper chelator Detapac was even more effective, reducing the degradation to 8-9%, and suggesting that the ROS responsible for the degradation were produced in the Fenton reaction. Dermal HA, and proteoglycans in both epidermis and dermis were not influenced by the treatments, indicating that the inhibition by SOD, catalase and Detapac on epidermal HA catabolism was specific. It is suggested that endogenous ROS is involved in the catabolism human epidermal HA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358242     DOI: 10.1016/s0891-5849(97)00098-1

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  41 in total

Review 1.  Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells.

Authors:  Paul L Bollyky; Ben A Falk; Rebecca P Wu; Jane H Buckner; Thomas N Wight; Gerald T Nepom
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

Review 2.  Hyaluronan fragments as mediators of inflammation in allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2014-12-31       Impact factor: 3.144

Review 3.  Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?

Authors:  Emmanuel Lorne; Hervé Dupont; Edward Abraham
Journal:  Intensive Care Med       Date:  2010-08-06       Impact factor: 17.440

4.  Regulation of cardiac cushion development by hyaluronan.

Authors:  T D Camenisch; J Biesterfeldt; T Brehm-Gibson; J Bradley; J A McDonald
Journal:  Exp Clin Cardiol       Date:  2001

Review 5.  Stromal reengineering to treat pancreas cancer.

Authors:  Ingunn M Stromnes; Kathleen E DelGiorno; Philip D Greenberg; Sunil R Hingorani
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

6.  Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis.

Authors:  Laura M Chang; Prateesh Maheshwari; Sheila Werth; Lana Schaffer; Steven R Head; Carrie Kovarik; Victoria P Werth
Journal:  J Histochem Cytochem       Date:  2011-01-12       Impact factor: 2.479

Review 7.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

Review 8.  Hyaluronan-dependent pericellular matrix.

Authors:  Stephen P Evanko; Markku I Tammi; Raija H Tammi; Thomas N Wight
Journal:  Adv Drug Deliv Rev       Date:  2007-08-14       Impact factor: 15.470

9.  Hyaluronan up-regulation is linked to renal dysfunction and hearing loss induced by silver nanoparticles.

Authors:  Hao Feng; Ilmari Pyykkö; Jing Zou
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-01       Impact factor: 2.503

10.  CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta.

Authors:  Paul L Bollyky; Ben A Falk; S Alice Long; Anton Preisinger; Kathy R Braun; Rebecca P Wu; Stephen P Evanko; Jane H Buckner; Thomas N Wight; Gerald T Nepom
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.